Recruiting Participants for Clinical Trial of Stem Cell Therapy for Cerebrovascular Disease in Patients with Vascular Dementia
Recruitment of participants for clinical trials of “cerebrovascular disease stem cell therapy” for patients with vascular dementia. 【Health Digest | Reporter Choi Min-young】 Cerebrovascular disease strikes unexpectedly. When a blood vessel supplying blood to the brain becomes blocked, a “cerebral infarction” occurs, and when it bursts, a “cerebral hemorrhage” occurs. Selpia Clinic, a stem cell regeneration clinic, announced on the 23rd that it is recruiting volunteers for a clinical trial to apply regenerative medicine stem cell therapy to treat vascular dementia, a cerebrovascular disease caused by brain tissue damage. The study targets patients under the age of 75 who have experienced recovery difficulties due to cerebral infarction or cerebral hemorrhage, have vascular dementia lasting more than three months, have shown minimal improvement despite medication, and have not seen any improvement in symptoms. This study, titled “The Effects of Autologous Blood-Derived Stem Cells on Patients with Vascular Dementia,” will examine the effects of selectively isolating cells from autologous blood and injecting them into the blood vessels that flow to the brain. The study will examine the effects of autologous blood-derived stem cells on improving dementia symptoms through neuroprotective effects and restoration of brain function. This clinical trial will utilize Miracell’s advanced stem cell extraction system, “Smart Mcell 2,” which has FDA registration and approval from the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, to extract highly safe stem cells. The BSC will be used to administer hematopoietic stem cells and various growth factors, including cytokines. Stem cells are progenitor cells that exist within the body. They are characterized by their outstanding regenerative ability, restoring damaged tissues to their original function. When stem cells are injected, the cells that migrate to the cerebral blood vessels are expected to regenerate cerebral vascular endothelial damage and strengthen existing blood vessels. The clinical trial uses autologous stem cells, so there are no side effects or costs. August 23, 2022
Miracell to Participate in Singapore Medical Fair 2022
Miracell to Participate in Singapore Medical Fair 2022 BoothIntroducing the “SMART M-CELL 2” Stem Cell Extraction System 【Health Digest | Reporter Choi Min-young】 Stem cell specialist Miracell (CEO Shin Hyun-soon) will showcase its stem cell extraction system, the “SMART M-CELL 2,” at the large-scale medical device exhibition “MEDICAL FAIR ASIA 2022,” held at Marina Bay Sands in Singapore from August 31st to September 2nd. The newly unveiled “SMART M-CELL 2” is an automated system capable of selectively isolating, extracting, and concentrating stem cells in just 17 minutes. Its key technology is its ability to maximize cell viability. This system automatically adjusts the RPM and angle of the separation vessel, reducing friction between vessels to minimize cell damage. Its closed system, which prevents air contact, is a bio-digital device equipped with LEDs that stimulate cell activity. Because it utilizes autologous bone marrow or blood, it is safe from immune rejection and side effects, and is used in hospitals and clinics nationwide, including university hospitals. According to the company, it has secured GMP, ISO 13485, ISO 9001, and European CE certifications, as well as 22 domestic and international patents for cell extraction technology, securing its source technology for stem cell technology. Following certification as a New Health Technology and Government Innovation Product, it recently completed FDA registration. CEO Shin Hyun-soon stated, “With the attention of many medical professionals and healthcare professionals at this year’s Singapore Medical Fair, Smart Mcell 2, a core system in regenerative medicine, is drawing closer to entering the global market.” Meanwhile, Miracell plans to participate in the ISAPS International Congress of Aesthetic Plastic Surgery, held in Istanbul, Turkey, from September 20th, and the IMCAS International Congress of Aesthetic Plastic Surgery, held in Bangkok, Thailand, from September 29th, to promote its advanced stem cell extraction system and expand exports.